Table 1.
Baseline characteristics of transgender women and transgender men who underwent gender affirming hormone therapy (GAHT).
| Transgender women |
Transgender men |
|||
|---|---|---|---|---|
| Already on GAHT (n = 46) | Hormone naïve (n = 59) | Already on GAHT (n = 15) | Hormone naïve (n = 25) | |
| Age | 43.9 ± 15.6 | 32.8 ± 11.7* | 40.4 ± 13.1 | 27.4 ± 8.8†* |
| Race (%) | ||||
| Caucasian | 52.1% | 71.2% | 66.7% | 68.0% |
| African American | 23.9% | 8.5% | 6.7% | 12.0% |
| Asian | 4.4% | 1.7% | 6.7% | 0% |
| Multiple | 0% | 1.7% | 6.7% | 4.0% |
| Unknown | 19.6% | 16.9% | 13.2% | 16.0% |
| BMI (kg/) | 26.3 ± 4.7 | 24.7 ± 4.7 | 26.6 ± 4.2 | 24.4 ± 5.4 |
| Height (Inches) | 69.7 ± 3.6 | 69.5 ± 2.4 | 64.6 ± 3.1† | 65.4 ± 3.1† |
| Weight (Pounds) | 182.6 ± 41.8 | 169.1 ± 34.6 | 158.6 ± 30.5† | 147.7 ± 34.5† |
| Years on Hormone | 6.6 ± 9.35 | 0 | 3.7 ± 3.43† | 0 |
Values are given as mean ± SD of the 46 transgender women who entered the cohort already on GAHT compared with 59 transgender women who entered the cohort before the initiation of GAHT and the 15 transgender men who entered the cohort already on GAHT and 25 transgender men who entered the cohort before the initiation of GAHT are in both comparisons. BMI, body mass index *P < 0.05 (p-values represent significance from log-transformed variables when relevant). We also compare transgender women to transgender men who already on hormone and transgender women to transgender men who hormone naïve. †P < 0.05 (p-values represent significance from log-transformed variables when relevant).